CJC-1295 with DAC – User Manual & Dosage Protocol Guide

CJC-1295 with DAC is a long-acting synthetic peptide analog of growth hormone-releasing hormone (GHRH) studied for its ability to stimulate endogenous growth hormone (GH) secretion over extended durations in research settings.

DAC (Drug Affinity Complex) is a modification designed to prolong peptide activity by increasing binding time in circulation.

Research Applications

• Growth hormone pulsatility and secretion studies
• IGF-1 modulation research
• Body composition and metabolic investigations
• Recovery and performance physiology models
• Healthy aging and sleep architecture studies

Disclaimer: CJC-1295 with DAC is for research and experimental use only and is not FDA-approved for general therapeutic use in this context.

Lyophilized Powder

Freeze-dried CJC-1295 with DAC for reconstitution

Reconstituted Solution

Subcutaneous research injection after preparation

CJC-1295 with DAC is studied for its ability to:

• Bind GHRH receptors in the pituitary to stimulate GH secretion
• Enhance GH pulse amplitude and frequency in investigational models
• Increase downstream IGF-1 signaling
• Provide prolonged stimulation due to DAC extended half-life characteristics

Effects are primarily observed in investigational and preclinical protocols.

There is no approved dosage outside regulated clinical use. The following reflects common research patterns only.

Subcutaneous (SC) Research Model

Subcutaneous (SC) Administration

Typical range: 500–1000 mcg

Frequency: 1–2 times weekly

Notes: Long-acting; less frequent dosing compared to non-DAC variants

Higher-Range Research

Typical range: 1000–2000 mcg

Frequency: Once weekly

Notes: Used in some IGF-1 response models

Due to its extended activity, daily administration is typically not used in research patterns.

Initiation Phase

Duration: 1–2 weeks

Purpose: Response and tolerance evaluation

Active Study Phase

Duration: 8–12 weeks

Purpose: GH/IGF-1 and body composition observation

Extended Model

Duration: Up to 16 weeks

Purpose: Longer-term endocrine outcome monitoring

Rest Period

Duration: 2–4 weeks

Purpose: Reset between study cycles

Cycle duration depends on research endpoints and design.

Supplies

• Sterile bacteriostatic water
• Sterile syringe
• Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.

• Example: 2 mg vial + 2 mL → 1 mg/mL

1. Swirl gently to dissolve (do not shake).
2. Refrigerate at 2–8°C after reconstitution.
3. Use within 2–4 weeks or per research protocol.

Avoid vigorous shaking to preserve peptide stability.

Subcutaneous Injection Model

• Common sites: abdomen, thigh, upper arm
• Clean site prior to administration
• Inject slowly
• Rotate sites to reduce irritation

Because it is long-acting, research designs typically schedule injections on consistent weekly days.

Lyophilized Powder

Storage: Cool, dry environment

Shelf life: Up to 12 months

Reconstituted Solution

Storage: Refrigerated (2–8°C)

Shelf life: 2–4 weeks

Protect From:

Light, heat, and contamination

Discard if the solution becomes cloudy or discolored.

• Research use only
• Not for general therapeutic application
• Human safety outside controlled research is not established
• Possible research observations may include:
• Injection-site irritation
• Headache
• Transient flushing
• Water retention or mild edema (GH-axis related)

IGF-1 monitoring is commonly used in investigational settings.

Maintain sterile handling technique at all times.

Keep out of reach of children.

Peptide: CJC-1295 with DAC
Category: Growth Hormone Axis / Long-Acting GHRH Research
Delivery: Subcutaneous research model
Typical Investigational Range: 500–2000 mcg weekly (1–2 injections)
Cycle: 8–12 week research designs
Storage: Refrigerated after reconstitution